Biotech Values

[DewDiligence]

>> I believe lucentis has shown in their 6 month data an improvement in over 40 percent of their subjects. <<

drbio: I am unclear about which Lucentis data set you are referring to. Can you clarify?

--
Surprised you are not a fan of OXGN given your affinity for other under-appreciated bios. I think it’s a tossup whether GENR or OXGN is first to partner their program in ophthalmology. GENR is further advanced in the development program, of course, but OXGN’s tie-in with the Wilmer Institute may be a significant factor for prospective partners.